Based on the abovementioned results, in the setting of NSCLC patients with both EGFR mutation and PD-L1 positivity, immunotherapy is suggested to be withheld temporarily to ensure both efficacy and safety, whereas it still remains an alternative once patients develop TKI resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.